These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34999541)

  • 1. The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor.
    Chen X; Hong X; Chen G; Xue J; Huang J; Wang F; Ali WADS; Li J; Zhang L
    Transl Oncol; 2022 Mar; 17():101338. PubMed ID: 34999541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.
    Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T
    Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab.
    Ligorio F; Fucà G; Zattarin E; Lobefaro R; Zambelli L; Leporati R; Rea C; Mariani G; Bianchi GV; Capri G; de Braud F; Vernieri C
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan‑immune‑inflammation value as a novel prognostic biomarker in nasopharyngeal carcinoma.
    Su Z; Tang J; He Y; Zeng WH; Yu Q; Cao XL; Zou GR
    Oncol Lett; 2024 Jun; 27(6):252. PubMed ID: 38646495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
    Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
    Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between platelet-to-lymphocyte ratio and outcomes in HER2-positive advanced breast cancer patients treated with pyrotinib: a retrospective study.
    Hao L; Dong J; Yu H; Chen J; Han X; Pan Y
    Transl Cancer Res; 2023 Oct; 12(10):2726-2741. PubMed ID: 37969380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib.
    Takeda T; Yamada T; Tanimura K; Nakano T; Ishida M; Tachibana Y; Shiotsu S; Horiuchi S; Hibino M; Okada A; Chihara Y; Takayama K
    Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib.
    Yang Y; Xu H; Yang G; Yang L; Li J; Wang Y
    Asia Pac J Clin Oncol; 2020 Feb; 16(1):63-69. PubMed ID: 31721468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
    Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
    Front Immunol; 2021; 12():724443. PubMed ID: 34777341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of alectinib in
    Jiang Y; Shi Y; Liu Y; Wang Z; Ma Y; Shi X; Lu L; Wang Z; Li H; Zhang Y; Liu C; Zhang S; Zhong Z; Lu J; Shi M; Shen B; Zhou G; Yin R; Galetta D; Grenda A; Romero A; Hughes BGM; Chen C; Wang X; Feng J
    Transl Lung Cancer Res; 2022 Dec; 11(12):2521-2538. PubMed ID: 36636415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.
    Provenzano L; Lobefaro R; Ligorio F; Zattarin E; Zambelli L; Sposetti C; Presti D; Montelatici G; Ficchì A; Martinetti A; Arata A; Del Vecchio M; Lauria Pantano C; Formisano B; Bianchi GV; Capri G; de Braud F; Vernieri C; Fucà G
    Ther Adv Med Oncol; 2023; 15():17588359231165978. PubMed ID: 37063779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer.
    Kayar R; Bastug Y; Tokuc E; Topaktas R; Akyurek EA; Kayar K; Artuk I; Ozturk M
    Int Urol Nephrol; 2024 Feb; 56(2):509-518. PubMed ID: 37773579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy.
    Şahin AB; Cubukcu E; Ocak B; Deligonul A; Oyucu Orhan S; Tolunay S; Gokgoz MS; Cetintas S; Yarbas G; Senol K; Goktug MR; Yanasma ZB; Hasanzade U; Evrensel T
    Sci Rep; 2021 Jul; 11(1):14662. PubMed ID: 34282214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
    Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
    J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer.
    Topkan E; Kucuk A; Ozkan EE; Ozturk D; Besen AA; Mertsoylu H; Pehlivan B; Selek U
    Discov Oncol; 2023 Dec; 14(1):230. PubMed ID: 38091179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab.
    Sánchez-Gastaldo A; Muñoz-Fuentes MA; Molina-Pinelo S; Alonso-García M; Boyero L; Bernabé-Caro R
    Transl Lung Cancer Res; 2021 Jun; 10(6):2509-2522. PubMed ID: 34295658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.